Shionogi & Co., Ltd.
Fiscal Year 2026 Q2 (Interim) Financial Results Presentation
For the first half, revenue was 350.4 hundred million yen, operating income was 115.2 hundred million yen, and net income attributable to owners of parent was 119.5 hundred million yen. Full-year forecasts were also revised upward, incorporating the IntraBio acquisition to continue growth.
Key Figures
- Revenue: 3,504 (Year-over-Year +103.1%)
- Operating Income: 1,152 (Year-over-Year +120.0%)
- EBITDA: 1,746 (Year-over-Year +103.4%)
AI要約
Overview of Results
In fiscal 2026 Q2, Shionogi & Co., Ltd. achieved revenue of 350.4 hundred million yen and operating income of 115.2 hundred million yen. Profitability increased significantly year-over-year, and EBITDA expanded to 174.6 hundred million yen. Strong royalty income, contributions from overseas subsidiaries and exports, and contributions from Torii Pharmaceutical-related products were key drivers. Full-year forecasts for FY2026 were also revised, assuming completion of the IntraBio acquisition.
Outlook and Investment Considerations
Full-year forecasts for FY2026 were revised upward. The outlook incorporates the launch of AQNEURSA following the IntraBio acquisition, recognition of intangible asset amortization, and strategic R&D investments, and expects continued revenue and profit growth. The financial policy also mentions a stance toward increasing the interim dividend and opportunities for share buybacks.
Revenue Trend
Operating Income Trend
EBITDA Trend
Revenue by Business Segment
Shionogi & Co., Ltd.
Company overview · Stock price · Financial data · All IR
